Drugs Health Pharma

US drug regulator FDA approves expanded use of Pfizer’s RSV vaccine

The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in.

Read More
Drugs Medical Pharma

Coronary drug-eluting stent market to grow 4% in India till 2033: Report

India’s coronary drug-eluting stent market may grow at a compound annual growth rate of 4% until 2033 on the back of a rise.

Read More
Drugs Health Pharma

Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.

Read More
Drugs Health Pharma

Body undergoes tectonic molecular shifts at age 44, 60: Stanford Medicine

Molecules and microorganisms in the human body dramatically rise or fall at an average age of 44 and 60 affecting both the heart.

Read More
Drugs Health Pharma

J&J plans to acquire Israel’s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

Read More
Drugs Health Pharma

Alcohol claims 2.6 million lives yearly, 209m people are dependent: WHO

About 400 million people globally live with alcohol and drug use disorders and of the total, 209 million people have alcohol dependence, according.

Read More
Drugs Health Pharma

Opinion: Feast for G20 leaders, benefits of millets exceed rice, wheat

By Dr. K. Leelamoni November 30, 2023: The move to serve Indian millet-based food, to G20 leaders in New Delhi in September 2023.

Read More
Drugs Health Pharma

Novo Nordisk stops testing of Ozempic as kidney trial meets efficacy goals

HQ Team October 11, 2023: Dutch pharmaceutical company, Novo Nordisk, has stopped testing Ozempic to treat the progression of renal impairment in people.

Read More
Drugs Health Pharma

FDA approves Lexicon’s oral drug for heart failure, type 2 diabetes patients

INPEFA is an inhibitor of both sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1). This class of SGLT inhibitors was recommended as.

Read More